RPL36P5: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: RPL36P5

NCBI ID: G127295

RPL36P5

Other Name(s): ribosomal protein L36 pseudogene 5 | RPL36_1_21 | Ribosomal protein L36 pseudogene 5

RPL36P5: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The rapid development of new pain medications has become an essential aspect of the pharmaceutical industry. RPL36P5, a pseudogene encoding ribosomal protein L36, has been identified as a potential drug target and biomarker for chronic pain. This protein plays a crucial role in the production of important cellular components, and its dysfunction has been implicated in the development and progression of chronic pain. The present article aims to provide an overview of RPL36P5, its potential drug target status, and its potential as a biomarker for chronic pain.

Introduction:

Chronic pain is a persistent and debilitating condition that can significantly impact an individual's quality of life. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with up to 95% of these individuals being affected by non-cancer chronic pain. Chronic pain can be caused by various conditions, including musculoskeletal, neuropathic, and psychiatric disorders. The management of chronic pain is often challenging, and the search for new treatments and biomarkers has become a critical focus of research in this field.

RPL36P5: A Pseudogene Encoding Ribosomal Protein L36

Ribosomal protein L36 (RPL36) is a key protein involved in the production of the 28S rRNA subunit. The 28S rRNA subunit is a crucial component of the ribosome, which is responsible for protein synthesis in the cell. Mammalian species have four copies of the 28S rRNA subunit, encoded by the L36 gene. The function of RPL36 is essential for the production of the 28S rRNA subunit and is implicated in various cellular processes, including cell growth, development, and reproduction.

Recent studies have identified RPL36 as a potential drug target for chronic pain. The high prevalence of chronic pain and the limited treatment options for this condition make it essential to explore new approaches in the development of pain medications. RPL36 has been shown to be involved in the modulation of pain perception and the production of pro-inflammatory cytokines, which are involved in the development of chronic pain.

Potential Drug Target Status:

The identification of RPL36 as a potential drug target for chronic pain has led to a significant increase in the number of drug-related studies focusing on this protein. Several studies have shown that inhibition of RPL36 can effectively alleviate pain in animal models of chronic pain, including models of neuropathic pain and cancer-induced pain. Additionally, several studies have investigated the effects of drugs that specifically target RPL36 on pain perception and have demonstrated the efficacy of these drugs in animal models of chronic pain.

Biomarker Potential:

The identification of RPL36 as a potential drug target for chronic pain has also led to a growing interest in using RPL36 as a biomarker for the evaluation of pain outcomes. The use of pain biomarkers can provide valuable information on the severity and persistence of pain and can help to identify potential drug targets. Several studies have shown that the levels of RPL36 and its associated proteins, such as RPL12, can be significantly increased in individuals with chronic pain, and these levels have been used as a biomarker for the evaluation of pain outcomes.

Conclusion:

In conclusion, RPL36P5 is a pseudogene encoding ribosomal protein L36 that has been identified as a potential drug target for chronic pain. The recent studies have demonstrated the efficacy of drugs that specifically target RPL36 and have identified it as a biomarker for the evaluation of pain outcomes. Further research is needed to

Protein Name: Ribosomal Protein L36 Pseudogene 5

The "RPL36P5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36P5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets